RE:RE:RE:An article on lung cancer Roswell Park is sponsoring two intraoperative NSCLC pdt phase 1 clinical trials with photofrin and light delivery with Lumeda's licensed optical surface applicator. Research conducted by Roswell Park researchers in collaboration with Dr. McFarland of this procedure (intraoperative pdt of NSCLC) with TLD-1433 led us to believe that TLD1433 was being considered for a phase 1 clinical trial.
Roswell Park chose to go with photofrin rather than TLD1433. There was no public communication from Roswell Park explaining why they made this choice. There was not even any public communication from RP that they were considering using TLD1433 in the first place. The research with Dr. McFarland seemed to speak for itself.
Roswell Park Sponsored IO-PDT of NSCLC Phase 1 Clinical Studies tdon1229 wrote: fredgoodwinson wrote: Yes FG - why didn’t Roswell run with TLD-1433 in those Trials? Did Theralase refuse them the licence? Are TLT themselves being denied use of the sensitisers licenced to them but developed by Sherri on US campuses? Is there some sort of stand off here to the benefit of Big Pharma?
My vague recollection (I'm not as old as Pandora, but I might be gaining on him) is that Roswell was using Photofrin and someone else's laser in a clinical trial. They were going to continue with those while retaining the option to include another arm with TLD1433 or some other alternate PDT of their own choosing. Can anyone confirm or correct?